Alnylam Pharmaceuticals Inc. jumped the most in almost 18 months after Sanofi agreed to pay $700 million for access to rare-disease treatments and a 12 percent stake in the biotechnology company.
The record discount in Roche Holding AG voting shares signals increasing speculation cross-town rival Novartis AG will sell its $14.1 billion stake into the market.
Novartis AG has a promising therapy for cancer. It’s just not sure how to get it to patients easily.
Novartis AG’s troubled acquisition of Chiron Corp.’s vaccine business has one last hope -- approval of a shot to protect against a meningitis-causing bacteria.
Actelion Ltd. Chief Executive Officer Jean-Paul Clozel has staked the future of the company he founded on an experimental drug that analysts say has a 63 percent chance of success.
Merck KGaA agreed to buy AZ Electronic Materials SA for about 1.6 billion pounds ($2.6 billion) in cash to boost its offering of specialty chemicals to the electronics industry.
Drugmakers led by Novo Nordisk A/S and Merck & Co. are increasing sales efforts for their top- selling diabetes drugs to grab as much of the market as possible ahead of a wave of new therapies.
Novartis AG plans to buy back $5 billion in stock over two years and said it will expand in faster-growing areas of health care such as treatments for skin and heart diseases.
Sanofi Chief Executive Officer Chris Viehbacher said the French drugmaker will return to earnings growth in the fourth quarter after the loss of patent protection on nine drugs in the past three years eroded profit.
Actelion Ltd. is once again shaping up as a takeover candidate after the lung-disease drug on which the company staked its future won regulatory approval.